Diabetes Core Update cover image

Diabetes Core Update – June 2023

Diabetes Core Update

00:00

The Effects of the PCSK9 Inhibitor on LDL Levels

The results were positive. We knew that a couple of months ago. The relative risk reduction in the PCSK9 inhibitor for the primary outcome was 15%. And this theoretically was in a statin intolerant population. So these are truly impressive results because it's a group of people who, and Jamie, I've heard you lecture on this topic, there's around 10% of our patients who don't take statins because they can't tolerate them. They have a higher incidence of bad outcomes of MI.

Transcript
Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app